Vaccine therapy for herpes simplex virus infections: An historical perspective

Reviews in Medical Virology

Volumn 6, Issue 2, 1996, Pages 85-96

  McKenzie, R ^a   Straus, S E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0011295869     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1099-1654(199606)6:2<85::aid-rmv167>3.0.co;2-e     Document Type: Article

References (64)

1. Jenner, E. (1798). An Inquiry Into the Causes and Effects of the Variolae Vaccinae. Low, London.
2. Cohen, J. (1994). Vaccines get a new twist. Science 264, 503-505.
3. Henderson, D. A. and Fenner, F. (1994). Small pox and vaccinia. In Vaccines, 2nd edn, ed. by S. A. Plotkin and E. A. Mortimer, pp. 13-40. W. B. Saunders Co., Philadelphia.
4. Plotkin, S. L. and Plotkin, S. A. (1994). A short history of vaccination. In, Vaccines, 2nd edn, ed. by S. A. Plotkin and E. A. Mortimer, pp. 1-11. W. B. Saunders Go., Philadelphia.
5. Horton, R. (1995). Myths in medicine: Jenner did not discover vaccination. BMJ 310, 62.
6. Pasteur, L. (1885). Methode pour prévenir la rage après morsure. C.R, Acad. Sei Paris 101, 765-772.
7. Burke, D. S. (1993). Vaccine therapy for HIV: A historical review of the treatment of infectious dis-eases by active specific immunization with microbederived antigens. Vaccine 11, 883-893.
8. Hektoen, L. and Irons, E. E. (1929). Vaccine therapy: Result of a questionnaire to American physicians. J. Am. Med. Assoc. 92, 864-869.
9. Yamanishi, K., Okuno, t. Shiraki, K. et al. (1988). Identification of human herpesvirus type-6 as a causal agent for exanthem subitum. Lancet 1, 10651067.
10. Moor, P. S. and Chang, Y. (1995). Detection of herpesvirus-Iike DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N. Engl J. Med. 332, 1181-1185.
11. Cesarman, E., Chang, Y., Moore, P. S., Said, J. W. and Knowles, D. M. (1995). Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332, 1186-1191.
12. Breinig, M. K., Kingsley, L. A., Armstrong, J. A., Freeman, D. J. and Ho, M. (1990). Epidemiology of genital herpes in Pittsburgh: sérologie, sexual, and racial correlates of apparent and unapparent herpes simplex infections. J. Infect. Dis. 162, 299-305.
13. Johnson, R. D., Nahmias, A. J., Magder, L. S., Lee, F. K., Brooks, C. A. and Snowden, C. B. (1989). A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N. Engl. J. Med. 321, 7-12.
14. Mertz, G. J., Schmidt, O., Jourden, J. L. et al. (1985). Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex. Trans. Dis. 12, 33-39.
15. Douglas, J. M., Vontver, A., Stamm, W. M. et al. (1985). et al. Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes. Antimicrob. Agents Chemother. 27, 203.
16. Lazar, M. P. (1956). Vaccination for recurrent herpes simplex infection: Initiation of a new disease site following the use of unmodified material containing the live virus. Arch. Dermatol 73, 70-71.
17. Blank, H. and Haines, H. G. (1973). Experimental human reinfection with herpes simplex virus. J. Invest. Dermatol. 61, 223-225.
18. Dix, R. D. (1987). prospects for a vaccine against herpes simplex virus types 1 and 2. Prog. Med. Virol. 34, 89-128.
19. Stanberry, L. R. (1990). Subunit viral vaccines: prophylactic and therapeutic use. In, Herpesviruses, the Immune System, and AIDS, ed. by L. Aurelian, pp. 309-341. Kluwer Academic Press, Norwell, MA.
20. Hull, R. N. and Peck, F. B. (1966). Vaccination against herpesvirus infections. Pan Am. Health Org. Sei. Publ 147, 266-275.
21. Kern, A. B. and Schiff, B. L. (1964). Vaccine therapy in recurrent herpes simplex. Dermatology 89, 844845.
22. Schmersahl, P. and Rudiger, G. (1975). Behandlungsergebnisse mit dem Herpes simplex-Antigen Lupidon H bzw. Lupidon G. Z Hautarzt 50, 105.
23. Dundarov, S., Andonov, P., Bakalov, B., Nechev, K. and Tomov, C. (1982). Immunotherapy with inactivated polyvalent herpes vaccines. Dev. Boil. Stan. 52, 351-358.
24. Weitgasser, H. (1977). Kontrollierte klinische Studie mit den Herpes-Antigenen Lupidon H und Lupidon G. Z. Hautkr. 52, 624-628.
25. Skinner, G. R. B., Fink, C. G., Durham, J. et al. (1989) Follow-up report on 101 subjects vaccinated with Skinner herpes vaccine. In, Vaccines for Sexually Transmitted Diseases, ed. by A. Meheus and R. E. Spier, pp. 202-207. Butterworths, London.
26. Skinner, G. R. B., Woodman, C. B. J., Hartley, C. E. et al. (1982). Early experience with 'antigenoid' vaccine Ac Nfu1; (S-) MRC towards prevention or modification of herpes genitalis. Dev. Biol. Stan. 52, 333-344.
27. Woodman, C. B. J., Buchan, A., Fuller, A. et al (1983). Efficacy of vaccine Ac Nfuj, (S-) MRC given after an initial clinical episode in the prevention of herpes genitalis. Br. J. Vener. Dis. 59, 311-313.
28. 27a. Benson, C. A., Turyk, M. E. and Wilbanks, G. D. (1995). A placebo-controlled trial of vaccination with a mixed glycoprotein herpes simplex virus type 1 vaccine for the modulation of recurrent genital herpes. In, IDSA 33rd Annual Meeting, San Francisco, CA, abstract 418.
29. Cappel, R., Sprecher, S., DeCuyper, F. and DeBraekeleer, J. (1985). Clinical efficacy of a herpes simplex subunit vaccine. J. Med. Virol. 16, 137-145.
30. Kutinovâ, L, Benda, R., Kalos, Z. et al. (1988). Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine 6, 223-228.
31. Mertz G. J., Ashley, R., Burke, R. L. et al. (1990). Double-blind, placebo-controlled trial of a herpes simplex virus type-2 glycoprotein vaccine in persons at high risk,for genital herpes infection. J. Infect. Dis. 161, 653-660.
32. Frenkel, L. M., Dillon, M. Garraty, E. et al. (1990). A randomized double blind, placebo-controlled phase 1 trial of a herpes simplex virus purified glycoprotein (gDl) vaccine. 30th Interscience Conference on Antibimocrobial Agents and Chemotherapy, Atlanta, GA, abstract 506.
33. Meignier, B., Longnecker, R. and Roizman, B. (1987). Construction and in vivo evaluation of two genetically engineered prototypes of live attenuated herpes simplex virus vaccines. In, Vaccines 87, ed. by R. M. Chanock, pp. 368-373. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
34. Meignier, B., Longnecker, R. and Roizman, B. (1988). In vivo hehavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis. 158, 602-614.
35. Meignier, B., Martin, B., Whitley, R. J. and Roizman, B. (1990). In vivo behavior of genetically engineered herpes simplex viruses 7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162, 313-321.
36. Cadoz, M. Micoud, M., Seigneurin, J. M. et al. (1992). Phase 1 trial of R7020: a live attenuated recombinant herpes simplex virus (HSV) candidate vaccine. In, 32nd ICAAC, Anaheim, ÇA, abstract 341.
37. Whitley, R. J. (1993). Prospects for vaccination against herpes simplex virus. Fed. Ann. 22, 726-732.
38. Whitley, R. J., Kern, E. R., Chatterjee, S., Chou, J. and Roizman, B. (1993). Replication, establishment of latency, and induced reactivation of herpes simplex virus 34.5 deletion mutants in rodent models. J. Clin, Invest. 91, 2837-2843.
39. Forrester, A., Farrell, H., Wilkinson, G. et al. (1992). Construction and properties of a mutant herpes simplex virus type 1 with glycoprotein gH sequences deleted. J. Virol. 66, 341-348.
40. McLean, C. S., Erturk, M, Jennings, R. et al. (1994). protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J. Infect. Dis. 170, 1100-1109.
41. Wachsman, M., Aurelian, L, Smith, C. C., Lipinskas, B. R., Perkus, M. E. and Paoletti, E. (1987). Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. J. Infect. Dis. 155, 1188-1197.
42. Cremer, K. J., Mackett, M., Wohlenberg, C., Norkins, A. L. and Moss, B. (1985). Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science 228, 737-740.
43. Rooney, J. F., Wohlenberg, C., Cremer, K. J. and Notkins, A. L. (1989). Immunized mice challenged with herpes simplex virus by the intranasal route show protection against latent infection. J. Infec. Dis. 159, 974-976.
44. Wachsman, M., Aurelian, L., Smith, C. C., Perkus, M. E. and Paoletti, E. (1989). Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease. J. Infect. Dis. 159, 625-634.
45. Rooney, J. F., Wohlenberg, C., Cremer, K. J., Moss, B. and Notkins, A. L. (1988). Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J. Virol. 62, 1530-1534.
46. McDermott, M. R., Graham, F. L, Hanke, T. and Johnson, D. C. (1989). Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B. Virology 169, 244-247.
47. Gallichan, W. S., Johnson, D. C., Graham, F. L. and Rosenthal, K. L. (1993). Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J. Infect. Dis. 168, 622-629.
48. Morein, B. and Simons, K. (1985). Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes. Vaccine 3, 83-93.
49. Ho, R. J. Y., Burke, R. L. and Merigan, T. C. (1989). Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs. J. Virol. 63, 2951-2958.
50. Sanchez-Pescador, L., Burke, R. L., Ott, G. and Van Nest, G. (1988). The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J. Immunol. 141, 1720-1727.
51. Burke, R. L., Goldbeck, C., Ng, P., Stanberry, L., Ott, G. and Van Nest, G. (1994). The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine.J. Infect. Dis. 170, 1110-1119.
52. Berman, P. W., Gregory, T., Grase, D. and Lasky, L. A. (1985). Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science 227, 1490-1492.
53. Stanberry, L. R., Bernstein, D. I., Burke, R. L. Pachl, C. and Myers, M. G. (1987). Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J. Infect Dis. 155, 914-920.
54. Burke, R. L., Hartog, K., Croen, K. D. and Ostrove, J. M. (1991). Detection and characterization of latent HSV RNA by in situ and Northern Blot hybridization in guinea pigs. Virology 181, 793-797.
55. Stanberry, L. R., Burke, R. L. and Myers, M. G. (1988). Herpes simplex virus glycoprotein treatment of recurrent genital herpes. J. Infect. Dis 157, 156-163.
56. Stanberry, L. R., Harrison, C. J., Bernstein, D. I. et al. (1989) Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy. Antiviral Res. 11, 203-214.
57. Eisenberg, R. J., Cerini, C. P., Heilman, C. J. et al. (1985). Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge. J. Virol. 56, 1014-1017.
58. Geerligs, H. J., Kocken, C. H. M., Drijfhout, J. W. et al. (1990). Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice. J. Gen. Virol. 71, 1767-1774.
59. Straus, S. E., Savarese, B., Tigges, M. et al. (1993). Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J. Infect. Dis. 167, 1045-1052.
60. Straus, S. E., Corey, L, Burke, R. l. et al. (1994). Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343, 1460-1463.
61. Langenberg, A. G. M., Burke, R. I., Adair, S. F. et al. (1995). A recombinant glycoprotein vaccine for herpes simplex type 2: safety and immunogenicity. Ann. Intern. Med. 122, 889-898.
62. Leroux-Roels, G., Moreau, E., Verhasselt, B. et al. (1993). Immunogenicity and reactogenicity of a recombinant HSV-2 glycoprotein D vaccine with or without mono-phosphoryl lipid A in HSV séronégative and seropositive subjects. 33rd ICAAC, New Orleans, LA, abstract 1209.
63. Leroux-Roels, G., Moreau, E., Desombere, I. et al. (1994). Persistence of humoral and cellular immune response and booster effect following vaccination with herpes simplex (gD2t) candidate vaccine with MPL. 34th ICAAC, Orlando, Fl, abstract H 57.
64. Committee on Issues and Priorities for New Vaccine Development (1985). In, New Vaccine Development: Establishing Priorities, pp. 280-312. National Academy Press, Washington, DC.